Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High – Here’s Why

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $30.74 and last traded at $30.65, with a volume of 482730 shares changing hands. The stock had previously closed at $29.22.

Analyst Ratings Changes

A number of brokerages recently issued reports on BCAX. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Guggenheim started coverage on Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 target price for the company. Bank of America assumed coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. Finally, Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.27.

Bicara Therapeutics Stock Performance

The company has a 50 day simple moving average of $22.83 and a two-hundred day simple moving average of $19.78. The company has a market cap of $1.96 billion, a PE ratio of -10.75 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, analysts expect that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current fiscal year.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, insider David Raben sold 5,500 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $22.88, for a total value of $125,840.00. Following the completion of the sale, the insider owned 55,286 shares in the company, valued at $1,264,943.68. This represents a 9.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 12,500 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00. Following the completion of the sale, the chief operating officer owned 196,141 shares of the company’s stock, valued at approximately $4,513,204.41. The trade was a 5.99% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,900 shares of company stock worth $1,420,704 in the last 90 days. 13.80% of the stock is owned by corporate insiders.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $45,000. Larson Financial Group LLC lifted its holdings in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.